Alex L Greninger
Overview
Explore the profile of Alex L Greninger including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
545
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ramirez S, Lopez P, Faraji F, Parikh U, Heaps A, Ritz J, et al.
bioRxiv
. 2023 Nov;
PMID: 37961119
T cells are involved in protective immunity against numerous viral infections. Data regarding functional roles of human T cells in SARS-CoV-2 (SARS2) viral clearance in primary COVID-19 are limited. To...
2.
Hao L, Hsiang T, Dalmat R, Ireton R, Morton J, Stokes C, et al.
Viruses
. 2023 Feb;
15(2).
PMID: 36851745
New variants of SARS-CoV-2 continue to emerge and evade immunity. We isolated SARS-CoV-2 temporally across the pandemic starting with the first emergence of the virus in the western hemisphere and...
3.
Dunkle L, Kotloff K, Gay C, Anez G, Adelglass J, Barrat Hernandez A, et al.
N Engl J Med
. 2021 Dec;
386(6):531-543.
PMID: 34910859
Background: NVX-CoV2373 is an adjuvanted, recombinant spike protein nanoparticle vaccine that was shown to have clinical efficacy for the prevention of coronavirus disease 2019 (Covid-19) in phase 2b-3 trials in...
4.
Mathieu C, Ferren M, Harder O, Bovier F, Marcink T, Predella C, et al.
Cell Mol Immunol
. 2021 May;
18(7):1835-1837.
PMID: 34007030
No abstract available.
5.
Elyanow R, Snyder T, Dalai S, Gittelman R, Boonyaratanakornkit J, Wald A, et al.
medRxiv
. 2021 Apr;
PMID: 33791723
Measuring the adaptive immune response to SARS-CoV-2 can enable the assessment of past infection as well as protective immunity and the risk of reinfection. While neutralizing antibody (nAb) titers are...
6.
Nakamichi K, Shen J, Lee C, Lee A, Roberts E, Simonson P, et al.
Sci Rep
. 2021 Feb;
11(1):4802.
PMID: 33637820
The COVID-19 epidemic of 2019-20 is due to the novel coronavirus SARS-CoV-2. Following first case description in December, 2019 this virus has infected over 10 million individuals and resulted in...
7.
Bosch D, Mathias P, Krumm N, Bryan A, Fang F, Greninger A
Clin Infect Dis
. 2021 Feb;
73(4):699-705.
PMID: 33564820
Background: An elevated white blood cell count (WBC; >15 000/μL) is an established prognostic marker in patients with Clostridium difficile infection (CDI). Small observational studies have suggested that a markedly...
8.
Boonyaratanakornkit J, Morishima C, Selke S, Zamora D, McGuffin S, Shapiro A, et al.
J Clin Invest
. 2020 Dec;
131(3).
PMID: 33320842
BACKGROUNDSARS-CoV-2-specific antibodies may protect from reinfection and disease, providing rationale for administration of plasma containing SARS-CoV-2-neutralizing antibodies (nAbs) as a treatment for COVID-19. Clinical factors and laboratory assays to streamline...
9.
Boonyaratanakornkit J, Morishima C, Selke S, Zamora D, McGuffin S, Shapiro A, et al.
medRxiv
. 2020 Oct;
PMID: 33052361
Background: SARS-CoV-2-specific antibodies may protect from reinfection and disease, providing the rationale for administration of plasma containing SARS-CoV-2 neutralizing antibodies (nAb) as a treatment for COVID-19. The clinical factors and...
10.
McCulloch D, Kim A, Wilcox N, Logue J, Greninger A, Englund J, et al.
JAMA Netw Open
. 2020 Jul;
3(7):e2016382.
PMID: 32697321
No abstract available.